Functional vascular endothelial growth factor - 2578 C/A polymorphism in relation to nasopharyngeal carcinoma risk and tumor progression

Clinica Chimica Acta

Volumn 395, Issue 1-2, 2008, Pages 124-129

  Nasr, Hela Ben ^a   Chahed, Karim ^a,b   Bouaouina, Noureddine ^a,c   Chouchane, Lotfi ^a,d  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b UNIVERSITY OF MONASTIR   (Tunisia)

^c FARHAT HACHED HOSPITAL   (Tunisia)

^d WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

Nasopharyngeal carcinoma; Polymorphism; Prognosis; Susceptibility; VEGF

Indexed keywords

VASCULOTROPIN;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR VOLUME; TUNISIA;

ADULT; ALLELES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS (GENETICS); RISK FACTORS; TUNISIA; VARIATION (GENETICS); VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47649097736     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.05.022     Document Type: Article

References (37)

1. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21 (2000) 505-515
2. Murono S., Inoue H., Tanabe T., et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma calls. Proc Natl Acad Sci USA 98 (2001) 6905-6910
3. Salven P., Teerenhovi L., and Joensuu H. A high pre-treatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90 (1997) 3167-3172
4. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362 (1993) 841-844
5. Howell W.M., Bateman A.C., Turner S.J., Collins A., and Theaker J.M. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 3 (2002) 229-232
6. Li Y.H., Hu C.F., Shao Q., et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Tansl Med 6 (2008) 1
7. Liu D.H., Zhang X.Y., Fan D.M., et al. Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinoma. World J Gastroent 7 (2001) 500-505
8. Aguayo A., Giles E., and Albitar M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic symdromes. Leukemia & lymphoma 44 (2003) 213-222
9. Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res 6 (2000) 1917-1921
10. Bayer-Garner I.B., Hough A.J., and Smoller M.D. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. Mod Pathol 12 (1999) 770-774
11. Guang-Wu H., Sunagawa M., Jie-En L., et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope 110 (2000) 2066-2069
12. Papazoglou D., Galazios G., and Koukourakis M.I. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod 10 (2004) 321-324
13. Yang B., Cross D.F., Ollerenshaw M., Millward B.A., and Demaine A.G. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications 17 (2003) 1-6
14. Jacobs E.J., Feigelson H.S., Bain E.B., et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8 (2006) 22
15. Olerup O., and Zetterquist H. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39 (1992) 225-235
16. Kim E.J., Jeong P., Quan C., et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 65 (2005) 70-75
17. Wei I W., and Shum J.S.T. Nasopharyngeal carcinoma. Seminar 365 (2005) 2041-2054
18. Pratesi C., Bortolin M.T., Bidoli E., et al. Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferenciated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55 (2006) 23-30
19. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12 (2001) 375-391
20. Shahbazi M., Fryer A.A., Pravica V., et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13 (2002) 260-264
21. Shimizu R., and Yamamoto M. Gene expression regulation and domain function of hematopoietic GATA factors. Semin Cell Dev Biol 16 (2005) 129-136
22. Labbaye C., Valtieri M., Barberi T., et al. Differential expression and functional role of GATA-2, NF-E2, and GATA-1 in normal adult hematopoiesis. J Clin Invest 95 (1995) 2346-2358
23. Yamashita K., Discher D.J., Hu J., Bishopric N.H., and Webster K.A. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol Chem 276 (2001) 12645-12653
24. Minami T., Murakami T., and Horiuchi K. Interaction between hex and GATA transcription factors in vascular endothelial cells inhibits flk-1/KDR-mediated vascular endothelial growth factor signaling. J Biol Chem 279 (2004) 20626-20635
25. Tamura M., Sebastian S., Gurates B., Yang S., Fang Z., and Bulun S.E. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells. J Clin Endocrinol Metab 87 (2002) 3504-3507
26. Schneider B.P., Radovich M., Sledge G.W., et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat (Sep 20 2007) [Electronic publication ahead of print]
27. Jin Q., Hemminki K., Enquist K., et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11 (2005) 3647-3653
28. Ke Q., Liang J., Wang L.N., et al. Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer. Mol Carcinog (Mar 31 2008) [Electronic publication ahead of print].
29. Kong S.Y., Park J.W., Lee J.A., et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 46 (2007) 446-455
30. Tzanakis N., Gazouli M., Rallis G., et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol 94 (2006) 624-630
31. Kawai Y., Sakano S., Korenaga Y., et al. Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 52 (2007) 1147-1155
32. Krishna S.M., James S., and Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 115 (2006) 85-90
33. Kim I., Moon S.O., Kim S.H., Kim H.J., Koh Y.S., and Koh G.Y. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276 (2001) 7614-7620
34. Freeman M.R., Schneck F.X., Gagnon M.L., et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55 (1995) 4140-4145
35. Ben Nasr H., Chahed K., Mestiri S., Bouaouina N., Snoussi K., and Chouchane L. Association of IL-8 (- 251) T/A polymorphism with susceptibility to and aggressiveness of nasopharyngeal carcinoma. Human Immunol 68 (2007) 761-769
36. Ben Nasr H., Chahed K., Bouaouina N., and Chouchane L. PTGS2 (COX-2) - 765 G > C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma. Mol Biol Rep (Oct 30 2007) [Electronic publication ahead of print].
37. Bhuvaneswari R., Gan Y.Y., Yee K.K., et al. Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma. Int J Mol Med 20 (2007) 421-428